TrialsgrambetaRCTs are beautiful

Fowler Daptomycin

2006

Daptomycin versus Standard Therapy for Bacteraemia and Endocarditis Caused by Staphylococcus aureus

In 246 patients with Staphylococcus aureus bacteraemia with or without endocarditis, daptomycin was non-inferior to an antistaphylococcal penicillin or vancomycin plus initial low-dose gentamicin for treatment success 42 days after the end of therapy, with less renal toxicity.

Result

Treatment success 42 days after the end of therapy
Absolute difference
2.5 points
Effect estimate

absolute difference2.495% CI -10.2 to 15.1

The absolute difference is derived from the event rates.

Also reported: Non-inferiority met. Clinically significant renal dysfunction 11.0 % vs 26.3 % (p=0.004).

Original publication
Subtopic
Antibiotic therapy
Design
Open-label non-inferiority RCT
Relevance
Important: one of several pillars.
Source
Fowler VG Jr, Boucher HW, Corey GR, et al. N Engl J Med. 2006;355(7):653-665.doi 10.1056/NEJMoa053783

Discussion & critique

Open-label and underpowered for the endocarditis subgroup, most of which was right-sided, so left-sided and prosthetic-valve disease remain untested. The nephrotoxicity of its gentamicin-containing control arm is a principal reason routine aminoglycoside combination therapy was abandoned in native-valve staphylococcal endocarditis.

Discussed in podcasts